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Respiratory disease represents an important component of small animal
emergency medicine. The morbidity and mortality of respiratory disease and
inflammation, although poorly defined, is considered to be significant. Much of the
therapy used in the stabilization and management of respiratory disease in veterinary
patients has been taken from human medicine, including inhalation therapy. Heparin has
been shown to have substantial anticoagulant, anti-inflammatory, and anti-fibrotic effects
within the lungs when administered via inhalation in human patients. To date, no studies
have evaluated the use of nebulized heparin in dogs. This study is the first to attempt to
generate pharmacokinetic data regarding nebulized unfractionated heparin in the dog.
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CHAPTER I
INTRODUCTION

Respiratory distress is a common reason for presentation in small animal
emergency and critical care medicine, and is associated with a significant mortality rate.
The exact percentage of veterinary patients presenting in respiratory distress is poorly
defined. Animals can present with true acute respiratory disease or an acute
manifestation of chronic respiratory disease. Determining whether the animal has
primary or secondary lung disease is important to aid in tailoring medical intervention
and therapy to optimize a successful outcome for the patient.
Common causes of respiratory distress in small animal medicine include thoracic
trauma, pneumonia (bacterial, viral, fungal, parasitic), interstitial lung diseases,
hemodynamic diseases (coagulopathies, anemia, thromboembolic disease), upper airway
obstructions, neoplasia, or respiratory manifestations of systemic disease. Regardless of
the primary cause, as more of the lung becomes compromised, secondary inflammation
can develop in the lungs, triggering acute lung injury (ALI) or acute respiratory distress
syndrome (ARDS). In both syndromes, noncardiogenic pulmonary edema develops
secondary to pulmonary vascular endothelial or alveolar epithelial injury.1 ARDS is
considered a more severe manifestation of ALI on the basis of the degree of hypoxemia
involved. Human and veterinary patients both tend to succumb to ALI/ARDS within two
weeks of developing the condition.
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Very little clinical or evidence-based medicine regarding the development and
treatment of ALI/ARDS in veterinary medicine exists. Current therapy is contingent on
early recognition of the disease process, is mostly based on supportive care, and is
focused on survival rather than prevention of long-term sequelae. Severe inflammation,
both in the respiratory tract as well as systemically, is a major contributing factor to
morbidity and mortality. Therapy is directed at trying to control the underlying disease
process as well as to limit the inflammatory response and inhibit fibrosis that may result
in impairment of pulmonary function.
Various treatment options have been tried and are being evaluated in human
medicine for the management and treatment of ALI/ARDS. Inhaled medications are
gaining popularity for their ability to act locally in the lung without displaying marked
systemic effects. One anti-inflammatory and anti-fibrotic treatment option that has
shown promise in human ALI/ARDS is inhaled heparin. In veterinary patients, the use of
heparin in an inhaled manner has not been fully evaluated. It has been shown that
unfractionated heparin exhibits similar pharmacokinetic properties in both humans and
dogs when administered subcutaneously.2 The same parallel activity would be expected
when heparin is administered via an inhaled route in the canine patient.
Acute Lung Injury/Acute Respiratory Distress Syndrome
ALI and ARDS have only recently been recognized as distinct disease entities in
veterinary medicine. Specific risk factors have been documented in veterinary patients
for the development of ALI/ARDS. In dogs, the most common associated diseases
include bacterial pneumonia, aspiration pneumonia, sepsis, and shock.3 Primary lung
disorders that have resulted in the development of ARDS in dogs include lung lobe
2

torsions, smoke inhalation, pneumonia (bacterial, aspiration, parasitic), strangulation,
pulmonary contusions, and hyperoxia.4 Secondary disorders that have resulted in ARDS
in dogs include babesiosis, pancreatitis, gastric and splenic torsion, sepsis, shock,
disseminated intravascular coagulation (DIC), and parvovirus.4 In cats, ARDS risk
factors are harder to define. ARDS has been suspected based on pulmonary necropsy
findings of septic feline patients.
The pathophysiology of ALI/ARDS has been documented in human medicine,
and the same pathophysiology is thought to occur in the small animal patient. ARDS is
thought to occur in three phases. The three phases are not distinct, but rather an
overlapping process of continued damage. The first phase, the exudative phase, is
characterized by increased pulmonary vascular permeability and infiltration by
inflammatory cells, resulting in the development of noncardiogenic edema. Type I
pneumocytes are irreversibly damaged. Type II pneumocytes replace the lost type I
pneumocytes and attempt to repair damage locally. In doing so, the stressed type II
pneumocytes decrease their production of surfactant. Surfactant deficiency results in
hyaline membrane formation and decreased oxygen exchange at the level of the alveoli.
Vascular endothelial damage results in local thrombosis and alveolar collapse.4 In human
patients with ARDS, this phase lasts approximately 7 days.5
The second phase of ARDS is the proliferative phase, in which the exudates from
phase I organize and fibrosis develops. Type II pneumocytes and fibroblasts proliferate
in an attempt to repair the on-going damage and inflammation. Initially, these changes
take place in the pulmonary interstitium. As the disease process progresses, the alveolar
lumen then becomes abnormal. These proliferative changes result in narrowing and,
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ultimately, collapse of the airways and airspaces.6 As more of the lung succumbs to the
disease, pulmonary hypertension ensues.5 An end-stage result of pulmonary hypertension
in some ALI/ARDS patients is right-sided heart failure.
In the final phase, termed the fibrotic phase, collagen deposits in the alveolar,
vascular, and interstitial beds. Microcysts, small cystic structures lined by pulmonary
epithelium and filled with fluid and debris, develop in the lungs. In human patients, the
amount of fibrosis that develops is thought to be a key predictor of survival of ARDS.7
Interestingly, in people who survive ALI/ARDS, pulmonary function can return to
normal in 6-12 months.8 In veterinary medicine, little is known about this phase or the
long-term effects of ALI/ARDS due to the high mortality rate in the earlier phases.4
Specific criteria for the diagnosis of ALI/ARDS have now been defined for
veterinary patients. Five categories of criteria were established for the diagnosis of
ARDS in veterinary patients. A patient must have at least 4, though ideally all 5, of the
criteria to be diagnosed clinically with ARDS. The five criteria include: 1) acute onset of
tachypnea/labored breathing at rest, greater than 72 hours in duration; 2) known risk
factors for the development of ARDS; 3) evidence of pulmonary capillary leak without
increased pulmonary capillary pressure, such as bilateral/diffuse infiltrates on thoracic
radiographs or CT; 4) evidence of inefficient gas exchange as determined by the ratio of
arterial oxygen tension to fractional inspired oxygen concentration (PaO2:FiO2), for ALI
and ARDS, the PaO2:FiO2 is less than 300 mmHg and 200 mmHg, respectively; 5)
evidence of diffuse pulmonary inflammation as based on an airway wash sample.1
Multiple therapies have been evaluated for the treatment of ALI/ARDS in human
medicine. There is no single best treatment option; rather, a multifactorial approach is
4

often necessary for a successful outcome. Ventilatory support, in combination with drug
therapy, provides the best survival results by allowing time for the damaged lung to
recover. The treatment options that have been evaluated and that are most promising are
based on the specific cytokines that have been implicated in the development and
progression of ARDS. Such cytokines include tumor necrosis factor-α (TNF-α),
interleukin-1 (IL-1), tumor growth factor-β (TGF-β), interleukin-6 (IL-6), plateletactivating factor, CXC chemokine ligand (IL-8), eicosanoids, and interleukin-10 (IL-10).9
Some of these cytokines are primarily pro-inflammatory, and some are antiinflammatory. Controlling the activity of these cytokines is difficult because of crossover in their activity depending on the stage of ARDS. Some of the drugs that have been
attempted in ARDS include albumin, corticosteroids, cyclooxygenase inhibitors, Nacetylcysteine, pentoxifylline, procysteine, prostaglandin E1, and surfactant. None of
those drugs has been shown to significantly affect morbidity or mortality in human
ARDS to date.10 Many of the same or similar drugs have been used in experimental
models of ARDS in dogs and cats with the same limited effects.4 Because of the lack of
positive response to therapy and substantial systemic side effects, inhalation therapy and
immunomodulatory therapy have become major areas of investigation in the management
of ALI/ARDS in both human and veterinary medicine.
Inhalation Therapy
Inhalation therapy has been the subject of intense research in the field of human
respiratory medicine. Inhalation therapy is also becoming increasing more popular in
veterinary medicine as more is learned from human medicine and research. The lung is
an important target for administration of medications because of several key features.
5

The alveolar surface area of the lung is large, providing a huge area for absorption. In
humans, the size of the alveolar surface varies between 80-140 m2 depending on the level
of distension of the lung.11 The lung also has a thin alveolar epithelial surface of 0.1-0.2
μm in thickness.12 Substances deposited in the lung have to travel a shorter distance
between the epithelial surface and blood then in other areas of the body (for example, the
intestinal epithelium) for absorption. The proteases and peptidases in the alveolar region
of the lungs are in lower quantities and activity than in other areas of the body such as the
gastrointestinal tract, meaning that the inhaled drugs will undergo slightly less proteolytic
degradation.13
There are several factors that must be overcome when utilizing the lungs as a
delivery vehicle for medications. The natural defense mechanisms of the upper airways
and bronchi consist of the mucociliary apparatus, epithelium, and lymphoid structures.
Particles of 2-3 μm or larger that are inhaled will primarily be deposited on the mucus of
the mucociliary apparatus, transported to the oropharynx, and swallowed.14 The presence
of inflammation, fluid, increased mucus, or fibrosis will also alter the ability of the lung
to absorb or clear particles. In the lower airways, the cell type encountered by the
particle may determine if the particle is absorbed or not. The lower airways are lined by
macrophages and lymphocytes with sparse neutrophils. Macrophages are normally the
only phagocytic cells encountered in the lower airways, although neutrophils and
lymphocytes can be induced to phagocytize particulate matter that enters the lower
airways. A substantial portion of any substance administered in an inhaled fashion will
be lost to the above defense mechanisms, leaving only a small amount to be absorbed for
local or systemic effects.
6

The method of delivery is a major factor in the amount of absorption and
bioavailability of inhaled drugs. Three major categories of delivery devices have been
developed for aerosol therapy. The first category includes nebulizers. Nebulizers are
available in three basic types: air-jet nebulizers, ultrasonic nebulizers, and vibrating plate
nebulizers. Air-jet nebulizers utilize a compressor that forces compressed air or oxygen
through a liquid substance, aerosolizing the liquid. With this type of nebulizer, the
structure of the drug can be altered by denaturation, shear-stress, or desiccation. A large
portion of the drug, as much as 95-99%, is recycled within the nebulization chamber
before ever even leaving the chamber, requiring long inhalation times for full delivery of
a specific dose.11 Ultrasonic nebulizers work by an electronic oscillator that generates a
high frequency ultrasonic wave on a vibrating element, disrupting the liquid surface of
the medication which aerosolizes the liquid in high concentration. These nebulizers work
best for larger substances that are not intended for deep lung delivery. Vibrating plate
nebulizers function by the use of a fine, vibrating mesh overtop a liquid reservoir. The
liquid is forced through the mesh, resulting in the production of a high fine-particle
aerosol. The vibrating plate nebulizers are not as efficacious for liposomal formulations
or suspensions of drug.11
The second category of aerosol delivery device is the metered dose inhaler (MDI).
MDIs are composed of set amounts of dissolved or suspended drug in a pressurized
propellant, most often chlorofluorocarbons. Spacing devices are often necessary with
MDIs as the aerosol is expelled with high velocity. These devices are convenient
because of their light weight and portability. However, for a drug to be used in an MDI,
it must meet specific requirements regarding particle size, stability within the device and
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propellant, and ability to withstand the nebulization process on expulsion. These
requirements often limit the utility of the device for most drugs. MDIs are most
commonly used in the management of asthmatic patients or patients with chronic
obstructive pulmonary disease.
Powered aerosols are the third method of delivery for inhalation therapy.
Powered aerosols are composed of preformed particles of a drug. The drug is stored as a
dried powder in a vehicle device. The energy necessary for dispelling the drug from the
device comes from the patient’s own inhalation. A patient must be able to fully inhale
for the drug to reach the deeper sections of the lung. The advantages of powdered
aerosols include stability of the drug, ease of use, portability, and often decreased cost.
Disadvantages include dependency on the patient’s ability to fully inhale, discrepancies
in consistent dosing, and susceptibility of the drug/device to environmental conditions
such as humidity. Drugs currently available and established as powdered aerosols
include steroids, β-mimetics, anticholinergics, antihistamines, and insulin. Powdered
aerosols have more limited use in veterinary medicine because of the reliance on the
patient fully inhaling the drug for dosing.
Once deposited in the alveolar space, a medication can be absorbed by four
different mechanisms: phagocytosis by alveolar macrophages, diffusion through tight
junctions, vesicular endocytosis or pinocytosis, and receptor-mediated transcytosis. The
size of the particle often determines the mechanism utilized.15 Previous studies have
shown that for particles up to 30,000 Da, only 20-50% of the total amount of drug
delivered to the alveoli will be available for systemic absorption and activity.16,17 A
substantial portion of the drug will be lost to the mucociliary epithelium on inhalation.
8

The remaining portion will be subject to phagocytosis by the alveolar macrophages
before coming in contact with pneumocytes. Most of the drug absorption occurs at the
level of the type I and II pneumocytes. Tight junctions located between the pneumocytes
regulate the transport of small particles, fluid, and ions. The tight junctions in the lungs
will accommodate diffusion of particles up to approximately 12 kDa.11 Vesicular
transport also occurs at the level of the pneumocytes. In type I pneumocytes, vesicular
transport can occur independent of hydrostatic or oncotic pressure gradients, allowing the
transport of both fluid and larger molecules. Type II pneumocyte vesicles are more
dependent on receptors and binding proteins for absorption of molecules.
Inhaled drug therapy was originally evaluated for the beneficial local effects
observed within the lungs. Early studies in inhalation therapy often focused on the
maximum amount of drug that could be administered without the development of
systemic side effects. More recently, investigations in inhalation therapy have focused on
the use of inhaled drugs to alter the respiratory environment for increased efficacy of
systemic medications as well as the use of medications in an aerosolized or nebulized
manner for systemic absorption and activity.
Heparin Therapy for Respiratory Disease
Heparin is an acidic, sulfated mucopolysaccharide that is widely used for its
anticoagulant properties. In the body, heparin is found in tissues with large amounts of
glycosaminoglycans such as the lungs and the intestinal tract. Heparin is stored in the
secretory granules of mast cells as well as in basophils. The most commonly used
formulation of heparin is unfractionated heparin, or heparin sodium. Heparin enacts its
anticoagulant activity by inhibiting the activated forms of factors II (thrombin) and X.
9

Heparin binds to plasma antithrombin, causing a conformational change in antithrombin.
This conformational change is necessary for the inhibition of the target enzymes,
activated factors X and IX (Xa and IXa), as well as for the formation of a complex of
heparin, antithrombin, and thrombin. This complex formation results in inhibition of
thrombin. Additional anticoagulant activities of heparin include its ability to reduce the
activity of factors V and VIII as well as inhibit platelet function by binding to platelet
factor 4. Other known activities of heparin include anti-inflammatory and
immunomodulatory effects such as inhibition of leukocyte recruitment, neutrophil
chemotaxis, neutrophil elastase, and numerous chemokines.18,19
Low-molecular-weight-heparin (LMWH) derivatives are also available for use as
anticoagulants. Current LMWHs include enoxaparin, dalteparin, certoparin, and
tinzaparin. They differ from unfractionated heparin in several important ways. LMWHs
are smaller in size, averaging between 4,000 – 6,000 Da, where unfractionated heparin is
approximately 15,000 Da.20 LMWHs also have significantly reduced thrombin activity.21
LMWHs also have a longer plasma half-life and higher bioavailability then
unfractionated heparin. LMWHs target anti-Xa activity rather then anti-thrombin
activity, resulting in a lower rate of side effects and a more predictable dose-response
relationship. LMWHs have become the mainstay of therapy for venous thrombosis,
while unfractionated heparin is the drug of choice for the acute management of arterial
thrombosis. For both unfractionated heparin and the LMWHs, the overall negative
charge and large size of the compounds prevent them from being absorbed when
administered orally. Therefore, heparin and its derivatives are most often administered
subcutaneously. Dosing intervals depend on the half-life of the drug. Unfractionated
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heparin has a half-life in plasma of approximately 1-2 hours, resulting in the need for
multiple injections to sustain the anticoagulant effects for a 24 hour period. The LMWHs
have a half-life of approximately 4-5 hours and can be administered less frequently for
sustained effect.22
The administration of unfractionated heparin and the LMWHs via an inhaled
route has been evaluated for both local anticoagulant and anti-inflammatory properties as
well as systemic anticoagulant effects. It has been determined that comparable blood
levels of both heparin and the LMWHs can be achieved when administered via deep
inhalation or given subcutaneously. Additionally, when administered via deep inhalation,
the heparin products have a more rapid onset of action.21 The dose of unfractionated
heparin that will result in systemic anticoagulant effects as determined by prolongation of
partial thromboplastin time (PTT) and anti-Xa activity when inhaled is 150,000 IU.23
The dose of unfractionated heparin that will result in clinical bleeding when inhaled is
greater than 400,000 IU.24 For the LMWH certoparin, an inhaled dose of 9,000 IU will
result in plasma anti-Xa levels greater than 0.2 U/mL, which is the level used for the
prophylaxis of venous thrombosis.20 For unfractionated heparin and the LMWHs,
inhaled dosing has not been found to result in a marked plasma peak following
administration. When the LMWH products are altered into liposomes or microspheres,
their resultant activity after inhalation can be prolonged, necessitating fewer
administrations for the same systemic anticoagulant effects.25,26
The local activity of heparin after inhalation has been evaluated in the face of
numerous respiratory diseases and conditions. Heparin has been shown to exert
profibrinolytic effects in the lung via inactivation of plasminogen activator inhibitor-1
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(PAI-1) when administered via nebulization; the same effects in the lungs were not noted
when heparin was administered systemically.27 Unfractionated heparin may enhance
airway clearance by increasing sputum expectoration.28 These findings have been
elucidated in models of human cystic fibrosis, pulmonary fibrosis, and COPD. Heparin
appears to increase the absorption and activity of itself and other nebulized drugs by
stimulating opening of the tight junctions of the pneumocytes in a transient and reversible
fashion.21 In a model of ALI and smoke inhalation in sheep, concomitant administration
of nebulized unfractionated heparin and antithrombin has been shown to prevent the
formation of fibrin casts.29 When administered with N-acetylcysteine via nebulization,
unfractionated heparin has resulted in reduced pulmonary failure, atelectasis, and
mortality in children with massive burn injury and smoke inhalation.30 In asthma models,
the LMWHs cause a reduction in allergen-induced bronchoconstriction and an inhibition
of the influx of inflammatory cells, especially eosinophils, to the lower airways.31 In a
model of early ALI, nebulized heparin appeared to make modest improvements in
pulmonary parenchymal inflammation, interstitial edema, microvascular thrombosis,
alveolar fibrin deposition, and fluid accumulation. However, these findings were not
statistically significant and the study population was small.32 Heparin and the LMWH
derivatives are able to exert their anticoagulant and anti-inflammatory properties without
substantial local side effects in regards to lung function and compliance. It also appears
that with chronic administration of inhaled heparin, the dose administered can be
decreased while still maintaining steady-state activity in the alveolar space.23
Although the vast majority of the research that has been done in regards to inhaled
heparin therapy has utilized animal models, the disease conditions investigated have been
12

simulated to mimic human respiratory disease states. The animal models used have most
frequently been sheep, rabbits, mice, and rats. Canine models have been infrequently
used considering the similarities in heparin activity between humans and dogs. Scant
research has been done to establish the use, pharmacokinetics, and activity of heparin
when administered via inhalation or nebulization in the dog as a potential therapeutic
agent for canine patients. Inhaled heparin could serve as a novel therapy for respiratory
diseases of both dogs and cats. The research presented in the following section of this
manuscript reflects a preliminary step in developing an understanding of the use of
inhaled heparin in the healthy canine lung. Once the pharmacokinetics of inhaled heparin
have been established in the healthy dog, the use of inhaled heparin in different canine
respiratory and systemic disease states can be evaluated.
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CHAPTER II
PHARMACOKINETICS OF INHALED HEPARIN IN THE DOG

Introduction
Inflammation, both systemically and locally, is a major contributing factor to
morbidity and mortality for many diseases in both human and veterinary medicine.
Therapy is typically directed at controlling the underlying disease process, while
concurrently limiting the inflammatory response and inhibiting the fibrosis that may
subsequently develop. Although more commonly considered an anticoagulant therapy,
heparin (including unfractionated heparin and low-molecular weight heparin derivatives)
has anti-inflammatory properties, and is a mainstay in the treatment of certain
inflammatory conditions in people, including rheumatoid arthritis, asthma, and
inflammatory bowel disease.1 Besides high affinity binding to antithrombin, which
greatly enhances antithrombin’s anticoagulant properties, heparin has potential to bind
many other proteins, including pro-inflammatory molecules.2,3 The mechanisms
responsible for the anti-inflammatory effects of heparin are not completely understood,
but are thought to include neutralization of the release of pro-inflammatory mediators
from inflammatory cells, binding to chemokines, cytokines, and complement factors,
prevention of interactions with pro-inflammatory receptors, and inhibition of several
endothelial adhesion molecules.4,2,1,5 Numerous studies in veterinary medicine have
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evaluated the use of heparin in inflammatory conditions; however, this medication is still
primarily used for its anticoagulant properties.
In both human and veterinary medicine, heparin is most commonly administered
via an intravenous or subcutaneous route. With the administration of heparin via
injection, the systemic effects are significant. Unfortunately, especially for
unfractionated heparin, the duration of action is short lived, requiring either frequent
injections or continuous rate infusions. The anti-inflammatory and anti-fibrotic benefits
of heparin administered via an inhaled route are currently being evaluated in human
patients, specifically for use in the management of acute respiratory distress syndrome
(ARDS), acute lung injury (ALI), and venous thromboembolism.6,7 The use of inhaled
heparin in human patients with chronic lung diseases such as pulmonary fibrosis, asthma,
and cystic fibrosis has also been evaluated.8,9,10 Inhaled heparin appears to have a longer
duration of action when compared to the subcutaneous route.3 The inhaled route of
administration may also have a more rapid onset of systemic anticoagulant activity.11
Unfractionated heparin exhibits similar pharmacokinetic properties in both
humans and dogs.12 The dosage for subcutaneous administration of unfractionated
heparin is similar for both dogs and humans, at 200 U/kg.13 Additionally, in both species,
there is a wide range of inter-individual variation in heparin’s pharmacokinetic and
pharmacodynamic profile. This variation has resulted in the recommendation of treating
patients with an individually adjusted heparin dose.14,15 In all previous studies, the
pharmacokinetics of heparin in dogs have been evaluated following administration via an
intravenous or subcutaneous route. Only one study has evaluated the use of heparin in an
inhaled manner in dogs. That study evaluated the effects of inhaled heparin on
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bronchoconstriction in the canine model.16 The local and systemic anticoagulant effects
of inhaled heparin in the dog have not been fully evaluated.
Recently, several studies have evaluated the use of inhaled heparin in rabbits and
humans. In a study using rabbits, administration of heparin via the respiratory tract
produced blood levels comparable to those achieved via the subcutaneous route.11 In
humans, a recent study determined the threshold dose and tolerability of inhaled
unfractionated heparin in healthy adults and patients with idiopathic pulmonary fibrosis.
Both groups were administered a heparin dose of 150,000 IU via inhalation. Despite
evidence of systemic effects (prolonged partial thromboplastin time and increased antifactor Xa activity), no serious adverse events were noted. Additionally, based on
bronchoalveolar lavage fluid (BALf) analysis, the local anticoagulant effect persisted as
long as 72 hours after heparin administration. This local effect is considerably longer
than the systemic effect as indicated by the increase in the plasma anti-Xa activity.8
The goals of this study were to establish the threshold dose of inhaled heparin for
systemic effects in healthy dogs, and to generate pharmacokinetic data for inhaled
heparin. The main hypothesis was that the effects of inhaled heparin would be prolonged
when compared to the systemic anticoagulant effects, that the threshold dose for spillover
of anticoagulant effects from the alveolar space to the plasma would be similar to that
seen in people, and that inhaled heparin would exert effects on canine BALf similar to
those observed in humans.
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Materials and Methods
Animals
Six healthy female intact Walker hounds were used in the study. The mean age of
the dogs was 3 years (range 2 to 5 years), and their mean body weight was 25.8 kg (range
20.2 to 68.6 kg). Body weight was obtained at the beginning of the study and used to
calculate all subsequent doses. The dogs were not exposed to any medications or
vaccines for at least 1 month before initiation of the study. Prior to beginning the study,
the dogs underwent a health screen that included complete blood counts with differential,
serum chemistry panel, prothrombin time (PT), activated partial thromboplastin time
(aPTT), occult heartworm testing and thoracic radiographs. The dogs were acclimated to
the face masks that were used in the study to administer the heparin over a period of 3
weeks prior to beginning data collection. Animal use was approved by the Mississippi
State University Institutional Animal Care and Use Committee, and was in compliance
with the requirements at a facility accredited by the American Association for
Accreditation of Laboratory Animal Care.
Assay Development
Two dogs were anesthetized for the collection of BALf. This fluid was utilized in
the generation of a calibration curve which would relate the clotting time endpoint in the
aPTT assay to corresponding heparin concentration (IU/mL) in BALf. Anesthesia was
induced and maintained using acepromazinea (0.02 mg/kg IM), butorphanolb (0.2 mg/kg
IM), and propofolc (5 mg/kg IV). An 8 mm sheath diameter flexible endoscoped was used
to evaluate the airways for any gross abnormalities prior to sample collection. The
endoscope was then used to guide collection of BALf samples from the right middle lung
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lobe. The lung lobe was lavaged with a total volume of 60 milliliters of sterile salinee in
three 20 milliliter aliquots. The fluid collected was pooled, filtered through sterile gauze,
centrifuged at 200xg for 10 minutes at 4ºC to remove cells, and frozen at -40ºC prior to
analysis. Additionally, plasma was collected into sodium citratef from healthy dogs to act
as a control and to be used in the assessment of heparin activity. Samples were stored in
plastic sample vials and shipped on dry ice to Cornell University’s Comparative
Coagulation Laboratory.
Unfractionated heparing was diluted in BALf from two individual dogs in
increasing increments of 0.125 IU of heparin/mL of BALf, through a range of 0 IU/mL to
1.0 IU/mL heparin. The heparinized BALf dilution was combined with an equal volume
of pooled canine plasma as a source of clotting factors and fibrinogen, and an aPTT was
performed on the reaction mixture. As a control, unfractionated heparin was added to
imidazole buffered saline (pH 7.4) through the same dilution series and then combined
with plasma. The aPTT assessment on the collected BALf samples was measured similar
to routine plasma aPTT measurement. Briefly, 75 µL of BALf or heparin standard
solution was added to 75 µL of pooled citrated canine plasma from healthy donors and
100 µL of Actin® FS reagenth. Samples then were incubated for 3 minutes at 37ºC, and
clotting was initialized by adding 100 µL of CaCl2i (0.025 M). Heparin activity was then
calculated based on a standard curve generated for this project and reported in
International Units (IU)/mL.
Threshold Dose
Two different dogs were used to determine the threshold dose of inhaled heparin
that would prolong systemic aPTT. A face mask was placed around the muzzle of each
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dog, and 50,000 IU of sodium heparin was administered via inhalation using an
ultrasonic nebulizerj. The appropriate heparin dose was combined with sterile saline to a
total of 15 mLs, loaded into the nebulizer, and administered for 15 minutes. Following
heparin administration, blood was collected via jugular venipuncture and placed in a 3
mL glass vacutainer tube containing 3.2% sodium citrate for immediate aPTT evaluation.
The aPTT was assessed with a standard bead coagulometerk according to the
manufacturer’s specifications. If the aPTT was not prolonged outside the normal range,
each dog was administered additional heparin via inhalation, in increments of 10,000 IU.
Following each dose increase, blood was collected for immediate systemic aPTT
evaluation. This dose escalation continued until either the systemic aPTT was prolonged,
or a total heparin dose of 200,000 IU was administered. The total heparin dose was
determined based on the maximum total volume the nebulizer trough would hold.
In order to absolutely ensure direct delivery of the heparin to the pulmonary
vasculature, the same two dogs were anesthetized, intubated, and administered inhaled
heparin via the endotracheal tube. Each dog was placed under general anesthesia using
the previously mentioned anesthetic protocol, and administered inhaled sodium heparin
with the same ultrasonic nebulizer in a reverse dose escalation fashion. A reverse dose
escalation was chosen to minimize the anesthetic time while allowing for any systemic
prolongation of the heparin to be observed. Positive pressure ventilation was used to aid
in delivery of the nebulized heparin to the lower airways. The initial heparin dose was
200,000 IU, and the dosage decreased in 25,000 IU increments, with the lowest
administered dose being 175,000 IU. Following 15 minutes of heparin administration,
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blood was collected from the jugular vein and placed in 3.2% sodium citrate for aPTT
evaluation.
Pharmacokinetics
Two different dogs were placed under general anesthesia using the previously
mentioned anesthetic protocol. As performed in Phase I, an 8 mm endoscope was used to
evaluate the airways for gross abnormalities and conduct a bronchoaveolalar lavage of
the right middle lung lobe using 60 mLs of saline (three 20 mL aliquots). The collected
BALf was processed and stored in the same fashion as described in Phase I. After the
collection of this initial BALf, the ultrasonic nebulizer was used to administer the
heparin. Each dog was administered 200,000 IU of heparin through the endotracheal
tube. BALf was then collected 30 minutes post-heparin administration using the
previously described collection protocol, and the dogs were recovered from anesthesia.
BALf was subsequently collected 24, 48, 72, and 96 hours post-heparin administration,
with the dogs re-anesthetized each time using the previously described anesthesia
protocol.
The local anticoagulant pulmonary effects of the inhaled heparin were evaluated
by analysis of BALf. In the collected BALf samples, the anti-Xa activity and aPTT, as
previously described, were assessed. At Cornell, a commercial kitl was used to measure
anti-Xa activity, which has previously been validated in dogs.17 The samples were
analyzed according to the manufacturer’s instructions, including standards and quality
control materials. This one-step competitive inhibition assay is configured with a bovine
factor reagent and a chromogenic substrate of factor Xa, and does not require exogenous
antithrombin. Briefly, 50 L of test plasma (diluted 1:2 in sample buffer) was added to
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125 μL of substrate. Following 4 minute incubation, 125 μL of factor Xa reagent was
added to the sample. After a 30 second equilibration period, optical density (OD)
readings were taken at 2 second intervals for 60 seconds, and the delta OD of test plasma
was converted to Units anti-Xa activity per milliliter (U/mL) by regression on a three
point log-linear standard curve derived using calibrators containing known quantities of
low-molecular-weight heparin in pooled normal canine plasma. In addition, a canine
plasma control sample spiked with unfractionated heparin to contain 0.7 U/mL anti-Xa
activity was assayed simultaneously with each run of test samples.
Results
Assay Development
From the two dogs used in this portion of the study, ten mls of BALf was
collected from one dog, and eight mls was collected from the second dog. For both dogs,
increasing concentrations of heparin in BALf caused increasing prolongation of the
aPTT. (Figure 2.1) The heparin-spiked BALf from one dog generated a similar curve to
that obtained from heparin diluted in buffer, with close to a 10-fold prolongation at 1.0
IU/mL heparin concentration. The same 1.0 IU/mL concentration of heparin in BALf
from the second dog generated an approximately 3-fold prolongation of aPTT. Although
the source of BALf influenced the aPTT, spiked BALf from both dogs generated a
heparin dose-response curve. The generated curve of heparin activity in the BALf
demonstrates that the anticoagulant activity of heparin can be measured in canine BALf.
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Threshold Dose
After the initial dose of inhaled heparin, administered via face mask, the systemic
aPTT did not prolong in either dog. In fact, even at the maximal dose of 200,000 IU, and
at all heparin doses in between, the systemic aPTT did not exceed the normal reference
range of the analyzer. With the same dogs anesthetized, and a more direct delivery of
heparin to the lower airways, there was no prolongation of the plasma aPTT at any dose,
including the maximal dose of 200,000 IU. One dog received the initial 200,000 IU dose,
and the second dog received an initial 200,000 IU dose and a second dose of 175,000 IU.

Figure 2.1

Heparin activity (as reflected by activated partial thromboplastin time,

aPTT, in seconds) in experimental dog bronchoalveolar lavage fluid (BALf) compared
with healthy canine plasma (control). The generated curve demonstrates the activity of
heparin can be detected in normal canine BALf in a dose-response relationship.
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Pharmacokinetics
The pre-heparin aPTT for BALf from the two dogs were 16.2 and 17.3 seconds,
respectively. The aPTT for the control plasma diluted in buffer rather than BALf was
12.1 seconds. After the addition of unfractionated heparin (1 IU/mL) in buffer, the
control plasma sample exceeded 180 seconds, the upper limits of the analyzer. The BALf
aPTT results did not exceed the establish reference range, at any time point, after the
inhalation of unfractionated heparin.
Prior to heparin administration, there was no detectable anti-Xa activity (0 U/mL)
in plasma or BALf from either study dog or in the control plasma sample. The assayed
anti-Xa activity in the control plasma spiked to contain 1 IU/mL of heparin was 1.2
U/mL. Thirty minutes after heparin inhalation, the anti-Xa activity in BALf from Dog 1
was 0.1 U/mL, the lower limit of assay detection. At all other time points, there was no
detectable anti-Xa activity in BALf from either dog. (Table 1) (Table 2.1)

26

Table 2.1

Anticoagulant activity (aPTT and anti-Xa) in canine bronchoalveolar lavage
fluid (BALf)
S

ID

Tim
epoint

aP
TT (sec)

1

Dog 1

16

0

2

Dog 1

Bas
eline
30
mins
24
hrs
48
hrs
72
hrs
96
hrs
Bas
eline
30
mins
24
hrs
48
hrs
72
hrs
96
hrs

17

0.1

16

0

16

0

16

0

15

0

17

0

16

0

16

0

18

0

15

0

16

0

12

0

>

1.2

ample
#

3
4
5
6
7
8
9

Dog 1
Dog 1
Dog 1
Dog 1
Dog 2
Dog 2
Dog 2

1

Dog 2

1

Dog 2

0
1
1

Dog 2

2
Canine
control plasma:
Heparin in
plasma:

antiXa (U/mL)

.2
.3
.7
.2
.1
.6
.3
.7
.1
.8
.9

.1
180
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Discussion
Most commonly utilized for its anticoagulant properties, unfractionated heparin
has been extensively studied for use in numerous conditions in both human and canine
patients. Dogs and humans demonstrate similar pharmacokinetics of unfractionated
heparin whether administered intravenously or subcutaneously. The administration of
heparin via inhalation has rarely been reported in dogs, and the pharmacokinetic profile
of inhaled heparin in this species has not been established. In humans, when compared
to subcutaneous administration, inhaled heparin has a more rapid onset of systemic
anticoagulant activity and a longer duration of action.18 This study attempted to establish
the pharmacokinetic profile and anticoagulant effects of inhaled heparin in normal
healthy dogs.
In the initial phase of the study, our results indicate that canine BALf does not
eliminate the anticoagulant activity of unfractionated heparin detected by prolongation of
in vitro clotting time in the aPTT. The aPTT dilution series demonstrated that the
anticoagulant activity of heparin in BALf was dose-dependent. The aPTT values for
heparin-spiked BALf and canine control plasma were similar at heparin concentrations in
the range of 0.25 to 0.75 IU/mL. At a high concentration of 1 IU/mL, we observed some
inter-individual variability in aPTT prolongation suggesting differences among dogs in
heparin-protein binding in the BALf fluid, or non-heparin compounds in BALf that might
influence contact pathway activation in the aPTT. Additional experiments are needed to
further define the cause of this variability.
In the second phase of the study, we attempted to establish a threshold dose of
inhaled heparin that would produce systemic anticoagulant activity. As in humans, the
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threshold dose used in the study was defined as the dose of inhaled unfractionated
heparin that would cause a measurable increase in plasma aPTT or detectable (> 0.1
IU/mL) anti-factor Xa activity. In healthy humans, using the same starting dose (50,000
IU) as in this study, and the same incremental dose increase (10,000 IU), the inhaled
heparin threshold dose was found to be 150,000 IU.8 Because dogs and humans appear
to share similar heparin pharmacokinetic profiles after intravenous and subcutaneous
administration, it was anticipated that the canine threshold dose for inhaled heparin
would be at most 150,000 IU. However, the exact threshold dose of inhaled heparin in
the dog could not be determined because there was no measurable increase in plasma
aPTT values at any time point. Based on the results of this study, it does not appear that
inhaled heparin in healthy dogs, even at high drug dosages, has a pharmacokinetic profile
similar to humans. It is possible that a threshold dose of inhaled heparin in dogs could be
identified, however it was not clinically feasible to use doses above the maximal dose of
200,000 IU in our study (higher doses would have required more prolonged nebulization
times). We therefore did not attempt to administer inhaled heparin doses of greater than
200,000 IU.
This initial attempt to establish the canine threshold dose of inhaled heparin was
based on the standard human method of delivering inhaled heparin via ultrasonic
nebulization. After administering very high inhaled heparin doses via a face mask and
nebulizer without any change in systemic aPTT, there was concern that the anatomical
differences between dogs and humans, particularly in the size of the oral and nasal
cavities, may have prevented the nebulized heparin from reaching the lower airways for
adequate drug absorption. In humans, it is estimated that 80-90% of inhaled
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glucocorticoids are deposited in the oropharynx and swallowed, with only the remaining
10-20% of the medication entering the respiratory tract.19,20 Approximately eight percent
of an aerosolized unfractionated heparin dose reaches the lower respiratory tract in
humans.21 Given failure to achieve systemic effects using nebulized heparin inhaled via a
face mask, heparin was then administered with the assistance of positive pressure
ventilation through an endotracheal tube directly to the lower airways, ensuring direct
delivery of nebulized heparin at the greatest concentration to the respiratory tract for
absorption. However, despite the revised delivery method, the results of the systemic
aPTT were similar to results obtained using the face mask method, and comparable to a
previous study conducted in dogs. The previous study used a considerably lower heparin
dose (10,000 IU) than this study, which dose escalated up to a maximum dose of 200,000
IU.16
In the final phase of the study, a high dose of inhaled heparin was administered to
evaluate the local pharmacokinetic effects of the inhaled heparin on normal canine BALf.
In a recent human study, the inhalation of aerosolized heparin created a significant
prolongation in the BALf aPTT 24 hours post-nebulization, an effect that persisted for 72
hours post-inhalation.8 The aerosolization of heparin appears to provide a significant
improvement in the length of local anticoagulant effects when compared to parenteral
injection. Even with this prolongation in anticoagulant effects, the incidence of
hemorrhage in humans during inhaled heparin therapy, both locally within the respiratory
tract and systemically, is minimal. If heparin’s anticoagulant effects in dogs persisted for
72 hours, as in humans, the use of an aerosolized form of this medication could provide
substantial improvement in local anticoagulant efficacy in canine patients prone to
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conditions such as pulmonary thromboembolism. However, despite using a higher
heparin dose than used in humans, we did not detect persistent heparin activity in the
BALf in either dog studied. Only one dog, at one time point, demonstrated heparin
anticoagulant activity as evidenced by a slight increase in anti-Xa activity. However,
since only a single time point demonstrated trace anti-Xa activity, it is unlikely that this
transient effect would be of clinical benefit.
Given that pharmacokinetic responses with injectable heparin in humans and dogs
are comparable, it was surprising that there was a lack of detectable systemic
anticoagulant effects for the nebulized heparin protocol used in this study. This
difference in results for inhaled heparin could be related to the type of nebulizer used or
the particle size of the drug that reached the alveolar space. In this study, an ultrasonic
nebulizer was used. This type of nebulizer uses ultrasound to disrupt the surface of the
liquid and produce a high concentration of aerosol. With this type of nebulizer, the
temperature of the liquid will increase and potentially create some degree of denaturation
of inhaled medications. Fortunately, most medications used clinically for nebulization,
including heparin, are stable and do not typically undergo denaturation when
administered with an ultrasonic nebulizer.22 Another form of nebulizer, the air-jet
nebulizer, uses compressed air at high velocity to convert liquids into aerosols. The
shear-stress generated with this form of nebulizer can compromise the stability of certain
molecules. Using air-jet nebulizers, only one percent of the droplets produced will leave
the nebulizer, while the remaining liquid will undergo nebulization multiple times.22 The
size of the droplets generated with various types of nebulizers differs; the air-jet nebulizer
generates smaller particle droplets, and the ultrasonic nebulizer generates larger droplets.
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The mass median diameter (MMD) of particles generated with an air-jet nebulizer is
approximately 2 µm, while the MMD of particles generated with an ultrasonic nebulizer
is greater than 5 µm.9 Mimicking a study that assessed the safety and tolerability of
inhaled heparin in humans8, an ultrasonic nebulizer was used in this study. An air-jet
nebulizer, at a driving rate of 10 L/min, has been shown to provide the greatest heparin
dose to the lower respiratory tract due to the smaller particle size generated by this type
of nebulizer.21 However, aerosolized heparin particles can still be efficiently absorbed
with an aerodynamic diameter of greater than 5 µm, the size typically generated by an
ultrasonic nebulizer.18 Ultrasonic nebulizers are more commonly used in clinical
veterinary practice; as such, this type of nebulizer was chosen for the study. Particle size
was not measured in this study, and additional research would be necessary to determine
if the particle diameter and type of nebulizer would influence canine responses to inhaled
heparin. Although an air-jet nebulizer was not used to generate smaller aerosolized
heparin particles, this project reproduced an inhalant protocol using an ultrasonic
nebulizer that has been shown to effectively heparinize human patients.8
Despite the lack of any detectable inhibitory effects on coagulation, neither local
nor systemic, inhaled unfractionated heparin may still potentially provide beneficial antiinflammatory activity. In humans, heparin has been used for its anti-inflammatory
properties in rheumatoid arthritis23 and inflammatory bowel disease.24 Additionally,
inhaled heparin has been used as an effective therapy in humans to control chronic
inflammatory pulmonary diseases such as pulmonary fibrosis8, asthma9, and cystic
fibrosis.10 The inhalation of heparin has improved respiratory function in humans
suffering from asthma that has become refractory to other more conventional therapies.
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The dose used in human patients with inflammatory pulmonary diseases is 100,000 IU.
This dose is half of the maximal dose used in this study. In dogs, a much lower inhaled
heparin dose of 10,000 IU per sublobar segment resulted in a decrease in several proinflammatory eicosanoids (thromboxane B2 and the leukotrienes C4, D4, and E4)
without any evidence of anticoagulant effects.16 Given these previous findings and the
fact that the high doses of heparin used in this study had no detectable in vitro
anticoagulant effects, further exploration of the potential anti-inflammatory properties of
inhaled heparin in dogs is warranted. As in people, inhaled heparin could have the
potential to be a therapeutic option in dogs with inflammatory pulmonary diseases
without the risk of excessive anticoagulation and hemorrhage.
Materials, Instruments, and Supplies
a. Vedco Acepromazine maleate injection, Boehringer Ingelheim, St. Joseph, MO
b. Butorphanol tartrate injection, USP, Hospira, Lake Forest, IL
c. Propoflo (propofol), Abbott Animal Health, Abbott Park, IL
d. Evis Exera Flexible Endoscope, Olympus America, Center Valley, PA
e. 0.9% sodium chloride injection, USP, Hospira, Lake Forest, IL
f. 3.8% sodium citrate, Vacutainer tube, Becton Dickinson, Franklin Lakes, NJ
g. Heparin sodium injection, USP, APP Pharmaceuticals, Schaumburg, IL
h. Actin® FS reagent, Dade Behring, Newark, DE
i. Calcium chloride anhydrous, Sigma-Aldrich, St. Louis, MO
j. Invacare® StratosTM Compact Aerosol Compressor, Invacare Corp., Elyria, OH
k. Stago STA Compact CT Coagulation Analyzer, Diagnostica Stago, Parsippany,
NJ
l. Rotachrom Heparin, Diagnostica Stago, Parsippany, NJ
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CHAPTER III
CONCLUSION

Respiratory disease represents a substantial proportion of small animal emergency
medicine cases. The exact morbidity and mortality of patients presenting with respiratory
disease is ill-defined. Many of the causes of respiratory distress, both in regard to
primary lung disease and systemic processes, have been shown to be risk factors for the
development of acute lung injury(ALI)/acute respiratory distress syndrome(ARDS) either
through direct lung injury or as part of a generalized inflammatory process. 1 ARDS is
associated with a 25-40% mortality rate in human medicine.2 In veterinary medicine,
mortality associated with ALI/ARDS is close to 100%.3 ARDS is considered a
substantial risk factor for the development of systemic inflammatory response syndrome
(SIRS) and multiple organ dysfunction syndrome (MODS).4 More recently, it has been
proposed that ARDS is not a distinct disease process but rather the first organ system to
fail in MODS, which is then followed by the liver.5 Given the high mortality rates and
severity of these syndromes, novel therapies are being evaluated for use in both human
and veterinary medicine.
One group of medications that have become widely used in numerous respiratory
conditions in human medicine are heparin and the low-molecular-weight heparin
derivatives (LMWH). Heparin has been demonstrated to have significant antiinflammatory and anti-fibrotic effects beyond its traditionally accepted anticoagulant
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effects. In several recent studies evaluating the use of unfractionated heparin in
ALI/ARDS, heparin was shown to decrease ventilator-associated lung injury as well as
decrease markers of inflammation within the lungs.6,7 Heparin administered systemically
and via nebulization has also been documented to reduce pulmonary fibrosis.8,9,10 Only
one previous study evaluating inhaled heparin has used the dog as a model. That study
used the dog as a model for exercise-induced asthma in people, and assessed the role of
heparin in reducing bronchoconstriction.11 No pharmacokinetic information regarding
the use of inhaled heparin in the dog was generated in this previous study.
The study presented in this thesis is the first to evaluate inhaled heparin for use as
a potential therapy in the dog. In this study, unfractionated heparin was administered via
nebulization using an ultrasonic nebulizer in order to generate a pharmacokinetic profile
for inhaled heparin in the dog. The first requirement for evaluating inhaled heparin in the
dog was to determine if the activity of unfractionated heparin could be assessed in normal
canine bronchoalveolar lavage fluid (BALf). Heparin activity was assessed through
determination of activated partial thromboplastin time (aPTT). We found that heparin
activity could be detected in normal canine BALf, and that the activity of unfractionated
heparin in BALf appears to be similar to its dose-dependent activity in canine plasma.
Normal canine BALf did not appear to complex with or neutralize the activity of heparin.
In the second portion of this study, determination of a threshold dose of nebulized
heparin that would result in systemic anticoagulant activity (that is, prolonged aPTT and
anti-factor Xa activity in canine blood samples) was attempted. Our study modeled a
study performed in people where a threshold dose of inhaled heparin was determined and
then used in patients with idiopathic pulmonary fibrosis.8 The human study found that an
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inhaled dose of 150,000 IU of heparin resulted in increased aPTT and anti-factor Xa
activity. Given that unfractionated heparin has a similar pharmacokinetic profile in
people and dogs when administered via a subcutaneous route12, we anticipated a similar
threshold dose would be found in normal dogs. However, we were not able to document
a threshold dose of inhaled heparin, as the plasma aPTT did not prolong in any dog at any
dose. The highest dose of heparin we were able to administer was 200,000 IU, as this
was the maximum volume the trough of the nebulizer would hold. Additionally,
administration of the highest doses of heparin required nebulization times as long as 45
minutes. Although it is possible that the aPTT would have prolonged at even higher
heparin doses, the clinical applicability of administering heparin via nebulization in this
manner would be lost if extremely high doses were truly necessary for systemic
anticoagulant activity.
Initially, we administered the nebulized heparin with the use of a face mask
attached directly to the nebulizer. When systemic anticoagulant activity was not
detected, the route of administration was then changed as we suspected that a large
portion of the nebulized heparin was not reaching the lower airways because it may have
been trapped in the nasal cavity or upper airways. The possibility that the dogs were
breath-holding or taking insufficient breaths was also considered. However, the dogs had
been acclimated to the use of the face masks for a substantial time period prior to starting
the study, and breath-holding or insufficient breaths were therefore not suspected. In
order to investigate the possibility of upper airway heparin trapping, we then placed the
dogs under injectable anesthesia and administered the nebulized heparin via the
endotracheal tube with the assistance of positive pressure ventilation. Administration via
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the endotracheal tube eliminated the oral and nasal cavities as a potential source of the
problem. The use of positive pressure ventilation should theoretically have delivered the
heparin at higher doses into the lower airways. Again, no detectable systemic
anticoagulant activity was shown despite these changes in the method of administration.
In the final phase of this study, we attempted to evaluate any local anticoagulant
effects of inhaled heparin in the lungs themselves. In humans, the local anticoagulant
effects of inhaled heparin have been found to persist for up to 72 hours and have a halflife of approximately 28 hours.8 A high dose of 200,000 IU was chosen as it was the
maximum amount we could practically deliver with the nebulizer, and was higher then
our proposed threshold dose of 150,000 IU. Unfortunately, no biologically relevant
prolongation in either aPTT or anti-factor Xa activity was noted in the BALf at any time
point.
The lack of detectable local and systemic heparin activity in our study was
unexpected. It seems unlikely that heparin delivered directly to the alveoli via the
inhaled route is not effective in dogs. The problem more likely lies in the anatomical
differences between the upper airway of dogs and humans as well as the differences in
ease of inhalation therapy in general between the two species. Two possible areas that
warrant further investigation in the use of inhaled heparin would be the type of nebulizer
used as well as the particle size of the nebulized heparin. We elected to use an ultrasonic
nebulizer as it is the most common clinically used type of nebulizer in veterinary
medicine.13 Previous studies have also reported increased lung deposition of nebulized
substances with the use of an ultrasonic nebulizer as compared to an air-jet nebulizer.14,15
However, it has also been suggested that ultrasonic nebulizers are not appropriate for
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deep lung delivery because they produce particles of a larger size.16,17 An air-jet
nebulizer may have been able to deliver the heparin to the lower airways more reliably.
A previous study in cats was able to demonstrate that a radiopharmaceutical agent was
found in all lung fields and the lower airways after administration via an air-jet
nebulizer.18 The use of a different nebulizer type may also overcome the limitation of the
nebulizer trough size in this study, allowing for administration of higher doses of heparin
(above 200,000 IU) over a shorter period of time.
An additional area warranting further investigation in the use of inhaled heparin
relates to the particle size of the heparin once it is nebulized. The delivery and location
of aerosolized particles in the respiratory tract depends on the size of the particle as well
as the tidal volume, inspiratory flow rate, and ability to breath hold of the patient to
whom the medication is being administered. For delivery to the trachea, optimal particle
size is approximately 2-10 μm; for delivery to the lower airways, the ideal particle size is
0.5-5 μm.19 In the study with the radiopharmaceutical agent administered to cats, the
particle size of the agent was 1.3 μm.18 In regards to aerosolized heparin specifically, an
air-jet nebulizer has been shown to deliver a heparin particle size of 2.01-3.64 μm while
an ultrasonic nebulizer has been shown to deliver heparin particles in the range of 5.617.03 μm.20 Particle size of the nebulized heparin was not determined in this study.
Differences in particle size of various medications are overcome in human inhalation
therapy by having the patient take deep breaths and breath hold. Dogs are not amenable
to performing those procedures on demand, so particle size could be a limiting factor in
the use of certain medications in veterinary inhalation therapy.
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Inhalation therapy is becoming increasingly more popular and feasible in small
animal practice because of its many benefits. Drugs administered via inhalation can often
be administered in smaller amounts than would be required for systemic administration.
The risk of potential negative side effects is often lower when drugs are given via
inhalation, because systemic absorption can be minimized while directing therapy at the
problem area. Conversely, the lungs can also serve as a new route of delivery for
systemic administration of medications. Drugs that are currently being used in an
aerosolized manner in veterinary medicine include various antibiotics (especially the
aminoglycosides), glucocorticoids, and bronchodilators. Inhaled heparin has shown
promise for its anticoagulant, anti-inflammatory, and anti-fibrotic effects in human
medicine in numerous respiratory conditions. Despite an absence of local anticoagulant
effects, inhaled heparin could still be a beneficial therapeutic option in canine respiratory
diseases because of potential anti-inflammatory and anti-fibrotic effects. For this reason,
further research to establish the pharmacokinetic profile of inhaled heparin in the dog is
warranted.
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